The rapid increase in developed countries over the past 30 years in esophageal adenocarcinoma (EAC) suggests strongly environmental influences. Barrett?s esophagus (EAC), a precursor lesion for EAC, is increasing and associated with alterations in esophageal microbiota. Obesity, another risk factor for EAC, is associated with an altered gut microbiome. Gut bacteria are able to promote inflammation and cancer through activation of myeloid cells that contribute to regeneration and immunosuppression. In preliminary studies, we have examined microbiota and myeloid cells in our L2- IL-1? mouse model of BE. This mouse model shows alterations in the GE junction microbiome at 12 months compared to WT mice, and housing in germ-free (GF) conditions leads to reductions in inflammation, metaplasia and dysplasia. Under SPF conditions, L2-IL-1? mice fed a high fat diet (HFD) show alterations in the microbiome and increased GE junction tumors. GEJ metaplasia and dysplasia are also accelerated by treatment with proton pump inhibitors (PPIs), which alters gastric microbiota, and by IL-8 expression, which mediates myeloid responses to microbes. Finally, we have developed tools (HDC-EGFP and HDC-DTR mice) that allow us to track or ablate immature myeloid cells/MDSCs that respond to microbes and promote gastrointestinal tumors. We propose 3 specific aims: (1) Define the role of gut microbiota in BE/EAC using the L2-IL-1b mouse model. The GE junction microbiota will be analyzed during disease progression using 16S rRNA sequencing, and the role in EAC determined by GF housing or antibiotic suppression, as well as by colonization with defined flora. (2) Do obesity and PPIs promote BE/EAC in part through microbiota? We will examine the effect of bacterial eradication on BE progression by HFD or PPIs. We will examine changes in microbiota in obese or slender BE patients. (3). Do bacteria induce BE/EAC primarily through myeloid cells? We will examine changes in myeloid cell trafficking to the GEJ in L2-IL-1? mice in response to microbiota and IL-8 using HDC-EGFP crosses, and assess their functional role through ablation and adoptive transfer. Taken together, these studies will define the potential role of microbiota in BE/EAC progression.

Public Health Relevance

The goal of this project is to define further the role of changes in bacteria in the gastrointestinal tract, and the responding inflammatory cells, in the development of Barrett?s esophagus and esophageal adenocarcinoma. We will use extensively the mouse model of Barrett?s esophagus developed by our group, and the germ-free facility at MIT and eradication models developed at Penn to define the significance of bacteria. We will correlate these findings with analysis of human tissues from Project 3.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163004-07
Application #
9559404
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
7
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Kasagi, Yuta; Chandramouleeswaran, Prasanna M; Whelan, Kelly A et al. (2018) The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. Cell Mol Gastroenterol Hepatol 5:333-352
May, Michael; Abrams, Julian A (2018) Emerging Insights into the Esophageal Microbiome. Curr Treat Options Gastroenterol 16:72-85
Huo, Xiaofang; Zhang, Xi; Yu, Chunhua et al. (2018) Aspirin prevents NF-?B activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus. Gut 67:606-615
Chan, Daniel K; Zakko, Liam; Visrodia, Kavel H et al. (2017) Breath Testing for Barrett's Esophagus Using Exhaled Volatile Organic Compound Profiling With an Electronic Nose Device. Gastroenterology 152:24-26
Ma, M; Shroff, S; Feldman, M et al. (2017) Risk of malignant progression in Barrett's esophagus indefinite for dysplasia. Dis Esophagus 30:1-5
Kraft, Crystal L; Rappaport, Jeffrey A; Snook, Adam E et al. (2017) GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress. Oncotarget 8:102923-102933
Zakko, Liam; Lutzke, Lori; Wang, Kenneth K (2017) Screening and Preventive Strategies in Esophagogastric Cancer. Surg Oncol Clin N Am 26:163-178
Hayakawa, Yoku; Fox, James G; Wang, Timothy C (2017) The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models. Cell Mol Gastroenterol Hepatol 3:331-338
Zakko, Liam; Visrodia, Kavel; Wang, Kenneth K et al. (2017) Editorial: The Effect of Bias on Estimation of Improved Survival After Diagnosis of Barrett's Esophagus. Am J Gastroenterol 112:1265-1266
Lee, Yoomi; Urbanska, Aleksandra M; Hayakawa, Yoku et al. (2017) Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. Oncotarget 8:203-214

Showing the most recent 10 out of 53 publications